High-Dose Nicotinamide Riboside Supplementation Provides Benefits in Parkinson’s Disease: Clinical Findings

Objectives

To assess the safety of high-dose NR through the absence of clinically significant adverse events, and assess short-term tolerability and impacts on NAD+, as well as clinical severity of Parkinson's disease (PD).

Journal

Nature Communications

Key Outcomes

• High-dose NR supplementation was safe and well-tolerated with no related adverse events.
• NR did not alter whole blood homocysteine, or other major methyl donor groups, suggesting no impact on methyl donor group pool.
• NR significantly improved clinical symptoms of PD, suggesting augmenting NAD+ levels may have a symptomatic anti-Parkinson's effect..

Duration

4 weeks

Dose

3000 mg

Study Design

Randomized, double-blind, placebo-controlled, phase I clinical study in 20 idiopathic PD patients